MGNX Macrogenics Inc

Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

$19.78  -1.21 (-5.77%)
As of 09/17/2021 09:44:40 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/10/2013
Outstanding shares:  61,107,288
Average volume:  935,632
Market cap:   $1,682,283,639
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    556099109
ISIN:        US5560991094
Sedol:      BFDV8K0
Valuation   (See tab for details)
PE ratio:   -9.92
PB ratio:   3.96
PS ratio:   14.19
Return on equity:   -39.89%
Net income %:   -107.31%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy